Ganoderma lucidum 'Green Reishi'

Ganoderma lucidum 'Green Reishi' is a cultivated variant of reishi mushroom that produces polysaccharides — including exopolysaccharides (EPS) up to 2.49 g/L and intracellular polysaccharides (IPS) up to 4.8 g/L — which are its primary bioactive compounds of interest. Current evidence is limited to in vitro studies demonstrating antibacterial activity, with no human clinical trials conducted to date.

Origin & History

Ganoderma lucidum 'Green Reishi' is a cultivar variant of the medicinal mushroom native to Asia's hot and humid regions. It is cultivated on organic sawdust substrates amended with 20% wheat bran under controlled conditions (28°C, 95% RH, 1500 ppm CO2), yielding 250g fresh mushroom per kg dry substrate over 2-3 flushes in 4 months. Harvested fruiting bodies are processed via double-extraction methods or liquid-state fermentation to produce bioactive compounds.

Historical & Cultural Context

Ganoderma lucidum has been used in traditional Asian medicine systems, particularly in Chinese medicine where it is known as 'Lingzhi.' However, the research focuses on modern cultivation methods rather than historical applications or traditional indications for this specific 'Green Reishi' cultivar.

Health Benefits

• No human clinical evidence available - only in vitro antibacterial activity reported
• Traditional use in Asian medicine systems documented but without specific health claims verified
• Cultivation produces polysaccharides (EPS up to 2.49 g/L, IPS up to 4.8 g/L) - compounds of interest but no proven benefits
• Contains ganoderic acids (up to 582 mg/L in fermentation) - bioactive compounds without established clinical effects
• Evidence quality: No human trials found in research dossier

How It Works

Green Reishi's polysaccharides, particularly beta-glucans within the EPS and IPS fractions, are hypothesized to interact with pattern recognition receptors such as Dectin-1 and TLR-2 on immune cells, potentially stimulating macrophage activation and cytokine release. In vitro antibacterial activity may involve disruption of bacterial cell membrane integrity, though the precise molecular targets remain uncharacterized. Triterpene compounds common to Ganoderma species, such as ganoderic acids, may also inhibit enzymes like HMG-CoA reductase and NF-κB signaling pathways, though these have not been specifically confirmed for the Green Reishi variant.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were found for Ganoderma lucidum 'Green Reishi' in the research dossier. The only study mentioned evaluated antibacterial activity using in vitro methods but lacked human data, sample sizes, or PubMed citations. Clinical evidence for this cultivar variant is currently absent.

Clinical Summary

No human clinical trials have been conducted specifically on Ganoderma lucidum 'Green Reishi,' making it impossible to confirm efficacy or optimal dosing in people. Available evidence is restricted to in vitro laboratory studies reporting antibacterial activity and polysaccharide quantification during cultivation optimization. Traditional use in Asian medicine systems — including Chinese and Japanese herbal traditions — provides historical context but does not constitute verified clinical evidence under modern standards. The polysaccharide yields (EPS up to 2.49 g/L; IPS up to 4.8 g/L) are well-characterized in fermentation research, but whether these concentrations translate to therapeutic benefit in humans is entirely unknown.

Nutritional Profile

Ganoderma lucidum 'Green Reishi' shares the general nutritional framework of Ganoderma species with some strain-specific variations. Macronutrients (per 100g dry weight, approximate): Protein 10–18g (containing all essential amino acids, notably glutamic acid, aspartic acid, and leucine as dominant fractions); Carbohydrates 55–75g (predominantly structural polysaccharides and fiber); Dietary fiber 50–65g (high insoluble beta-glucan content); Fat 1–3g (predominantly unsaturated fatty acids including oleic and linoleic acid); Moisture in fresh fruiting body 85–92%. Key bioactive compounds: Beta-glucan polysaccharides — exopolysaccharides (EPS) documented at up to 2.49 g/L in liquid fermentation culture; intracellular polysaccharides (IPS) up to 4.8 g/L — these are (1→3)-beta-D-glucan and (1→6)-beta-D-glucan backbone structures with immunomodulatory interest but unconfirmed clinical efficacy; Ganoderic acids (triterpene family) — quantified at up to 582 mg/L in fermentation conditions, including ganoderic acids A, B, C, D, G, and H; bioavailability is limited by poor aqueous solubility and first-pass metabolism, enhanced by ethanol or hot-water extraction; Ergosterol (provitamin D2 precursor) 0.3–1.5 mg/g dry weight — converts to vitamin D2 upon UV exposure, though conversion in finished product depends heavily on processing; Minerals: potassium (dominant, ~1,800–3,500 mg/100g dry), phosphorus (~500–900 mg/100g dry), magnesium (~80–200 mg/100g dry), calcium (~20–80 mg/100g dry), zinc (~5–15 mg/100g dry), iron (~4–12 mg/100g dry), selenium trace amounts (~0.01–0.1 mg/100g dry, highly substrate-dependent); B-vitamins: riboflavin (B2) ~0.4–1.2 mg/100g dry, niacin (B3) ~5–10 mg/100g dry, pantothenic acid (B5) ~1–3 mg/100g dry; Adenosine and nucleosides present in small quantities (~0.1–0.5 mg/g dry); Lectins reported in fruiting body at low concentrations. Bioavailability notes: Raw fruiting body polysaccharides have low bioavailability due to chitin cell wall encapsulation — hot-water extraction or dual extraction (water + ethanol) significantly increases bioactive yield; ganoderic acids require alcohol-based extraction for meaningful recovery; the 'Green Reishi' color variant is associated with specific cultivation conditions (often cooler temperatures or particular substrate formulations) but nutritional differentiation from red Ganoderma lucidum strains is not robustly characterized in peer-reviewed literature — compositional differences are presumed minor but strain-validated data is limited.

Preparation & Dosage

No clinically studied dosage ranges are available for Ganoderma lucidum 'Green Reishi' as human trials are absent from the research. Double-extraction methods (water boiling 2-3 hours followed by dehydration) are used for processing, but consumption dosing remains unstudied. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other Reishi variants, Turkey Tail, Cordyceps, Lion's Mane, Vitamin D3

Safety & Interactions

Because no human trials exist for Green Reishi specifically, a complete safety profile has not been established, and side effects cannot be quantified with confidence. General Ganoderma lucidum preparations have been associated with mild adverse effects including digestive upset, dry mouth, and skin rash, and rare cases of hepatotoxicity have been reported with prolonged use of powdered whole mushroom products. Potential drug interactions include additive effects with anticoagulants such as warfarin — due to possible platelet aggregation inhibition by triterpenes — and theoretical interactions with immunosuppressants given the immunomodulatory properties of beta-glucans. Pregnant or breastfeeding individuals and those with autoimmune conditions or scheduled surgeries should avoid use until safety data specific to this variant are available.